Curated News
By: NewsRamp Editorial Staff
September 03, 2024
GeoVax Labs CEO to Present at Investor Events
Discuss on Reddit
Discuss on SubstackTLDR
- GeoVax Chairman and CEO, David Dodd, to speak at 26th Annual Global Investment Conference and Emerging Growth Conference, providing insight and potential investment opportunities.
- GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines for infectious diseases and therapies for solid tumor cancers, with a lead clinical program in COVID-19 vaccine development.
- GeoVax's clinical trials and product candidates aim to address infectious diseases and solid tumor cancers, potentially improving global health outcomes and saving lives.
- GeoVax's lead clinical program, GEO-CM04S1, is being evaluated as a primary vaccine for immunocompromised patients and as a booster vaccine in patients with chronic lymphocytic leukemia.
Impact - Why it Matters
This news matters as it highlights the latest developments and advancements in the biotechnology industry, especially in the development of vaccines for infectious diseases like COVID-19. It also provides insights into the ongoing research and clinical trials for innovative cancer therapies. Investors and individuals interested in the biotech and healthcare sectors will find value in this update.
Summary
GeoVax Labs, Inc. CEO David Dodd to present at H.C. Wainwright 26th Annual Global Investment Conference and Emerging Growth Conference. The company is developing immunotherapies, vaccines against cancers, and infectious diseases. It has a lead clinical program for a next-generation COVID-19 vaccine and a novel oncolytic solid tumor gene-directed therapy.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, GeoVax Labs CEO to Present at Investor Events
